Literature DB >> 11303695

Endothelial dysfunction and decreased exercise tolerance in interferon-alpha therapy in chronic hepatitis C: relation between exercise hyperemia and endothelial function.

B Takase1, A Uehata, T Fujioka, T Kondo, T Nishioka, K Isojima, K Satomura, F Ohsuzu, A Kurita.   

Abstract

BACKGROUND: We previously reported that reversible endothelial dysfunction is caused by interferon-alpha therapy (IFN) in patients with chronic hepatitis C. In experimental studies, limb blood flow during exercise is reported to be dependent on endothelium-derived nitric oxide. HYPOTHESIS: The purpose of this study was to confirm the effect of IFN on endothelial function and to investigate whether exercise hyperemia is dependent on endothelial function in humans.
METHODS: We performed symptom-limited exercise treadmill testing and measured flow-mediated vasodilation (FMD, endothelium-dependent vasodilation) and sublingual glyceryl-trinitrate-induced dilation (GTN-D, 0.3 mg, endothelium-independent vasodilation) in the brachial artery by using high-resolution ultrasound in 10 patients with chronic active hepatitis C (age 53 +/- 11 years, 2 men, 8 women) before and immediately after administration of recombinant interferon 2b (10 million U/day) for 4 weeks.
RESULTS: There were no significant abnormal findings in any patients in routine studies of 24-h ambulatory electrocardiogram monitoring, two-dimensional echocardiography, and exercise treadmill testing both before and after treatment. Leg fatigue and exhaustion were the reasons for termination of exercise treadmill testing in each patient. Pressure rate product was calculated at rest and peak exercise. Interferon-alpha therapy significantly (p<0.05) decreased FMD (6.8 +/- 3.1 vs. 1.9 +/- 2.6%), exercise treadmill testing tolerance time (437 +/- 89 vs. 395 +/- 62 s) and peak pressure rate product (283 +/- 41 vs. 241 +/- 47 mmHg x beats/min x 10(-2)), but not GTN-D (13.4 +/- 5.4 vs. 17.0 +/- 5.5%). The change of FMD due to IFN significantly and highly correlated with exercise treadmill testing tolerance time (r = 0.86, p<0.001), but not with change of peak pressure rate product, suggesting that FMD is more closely related to the condition of the peripheral circulation than is cardiac performance.
CONCLUSION: These results suggest that IFN in patients with chronic hepatitis C impairs endothelial function and exercise tolerance, and that endothelial function might be at least partly involved in exercise hyperemia in humans.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11303695      PMCID: PMC6654793          DOI: 10.1002/clc.4960240406

Source DB:  PubMed          Journal:  Clin Cardiol        ISSN: 0160-9289            Impact factor:   2.882


  7 in total

1.  Ophthalmological side effects of interferon therapy of chronic hepatitis C.

Authors:  Eman Medhat; Gamal Esmat; Eman Hamza; Amr Abdel Aziz; Waleed Fouad Fathalah; Samar Kamal Darweesh; Zeinab Zakaria; Sameh Mostafa
Journal:  Hepatobiliary Surg Nutr       Date:  2016-06       Impact factor: 7.293

Review 2.  Role of interferon alpha in endothelial dysfunction: insights into endothelial nitric oxide synthase-related mechanisms.

Authors:  Joy N Jones Buie; Jim C Oates
Journal:  Am J Med Sci       Date:  2014-08       Impact factor: 2.378

3.  A Drop in Hemoglobin as an Association with Pegylated Interferon Retinopathy: A Novel Pathophysiology.

Authors:  Meghan Berkenstock; Shaivi Patel; Jessica Ackert
Journal:  J Curr Ophthalmol       Date:  2020-04-30

Review 4.  Physical Exercise Protects Against Endothelial Dysfunction in Cardiovascular and Metabolic Diseases.

Authors:  Juan Gao; Xue Pan; Guoping Li; Emeli Chatterjee; Junjie Xiao
Journal:  J Cardiovasc Transl Res       Date:  2021-09-17       Impact factor: 3.216

5.  Interferon-alpha-associated presumed ocular sarcoidosis.

Authors:  Deshka Doycheva; Christoph Deuter; Nicole Stuebiger; Manfred Zierhut
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2008-11-26       Impact factor: 3.117

Review 6.  Anti-metastatic functions of type 1 interferons: Foundation for the adjuvant therapy of cancer.

Authors:  Angélica Ortiz; Serge Y Fuchs
Journal:  Cytokine       Date:  2016-01-25       Impact factor: 3.861

7.  The effect of type 1 IFN on human aortic endothelial cell function in vitro: relevance to systemic lupus erythematosus.

Authors:  John A Reynolds; David W Ray; Leo A H Zeef; Terence O'Neill; Ian N Bruce; M Yvonne Alexander
Journal:  J Interferon Cytokine Res       Date:  2014-01-20       Impact factor: 2.607

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.